- Home
- AQB vs SNOA Comparison
AQB vs SNOA Comparison
Compare AQB & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- SNOA
- Stock Information
- Founded
- AQB 1991
- SNOA 1999
- Country
- AQB United States
- SNOA United States
- Employees
- AQB N/A
- SNOA N/A
- Industry
- AQB
- SNOA Biotechnology: Pharmaceutical Preparations
- Sector
- AQB
- SNOA Health Care
- Exchange
- AQB Nasdaq
- SNOA Nasdaq
- Market Cap
- AQB 3.4M
- SNOA 3.7M
- IPO Year
- AQB N/A
- SNOA 2007
- Fundamental
- Price
- AQB $0.58
- SNOA $2.68
- Analyst Decision
- AQB Hold
- SNOA
- Analyst Count
- AQB 2
- SNOA 0
- Target Price
- AQB N/A
- SNOA N/A
- AVG Volume (30 Days)
- AQB 838.2K
- SNOA 290.3K
- Earning Date
- AQB 11-05-2024
- SNOA 02-06-2025
- Dividend Yield
- AQB N/A
- SNOA N/A
- EPS Growth
- AQB N/A
- SNOA N/A
- EPS
- AQB N/A
- SNOA N/A
- Revenue
- AQB $1,258,512.00
- SNOA $13,547,000.00
- Revenue This Year
- AQB N/A
- SNOA $23.89
- Revenue Next Year
- AQB $57.38
- SNOA $25.45
- P/E Ratio
- AQB N/A
- SNOA N/A
- Revenue Growth
- AQB N/A
- SNOA 11.81
- 52 Week Low
- AQB $0.47
- SNOA $2.44
- 52 Week High
- AQB $3.00
- SNOA $9.40
- Technical
- Relative Strength Index (RSI)
- AQB 30.45
- SNOA 47.23
- Support Level
- AQB $0.47
- SNOA $2.44
- Resistance Level
- AQB $1.00
- SNOA $3.25
- Average True Range (ATR)
- AQB 0.14
- SNOA 0.21
- MACD
- AQB -0.02
- SNOA -0.01
- Stochastic Oscillator
- AQB 21.18
- SNOA 29.63
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About SNOA Sonoma Pharmaceuticals Inc.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.